Axatilimab Uses, Dosage, Side Effects and more
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
| Trade Name | Axatilimab |
| Generic | Axatilimab |
| Axatilimab Other Names | anti-Csf1R monoclonal antibody SNDX-6352, Axatilimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Axatilimab works
Axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptors (CSF-1R). Its actions at CSF-1R allows for the regulation of the expansion and infiltration of donor-derived macrophages that mediate chronic graft versus host disease.
